Non‐cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production, and recurrent pulmonary infections. Non‐cystic fibrosis bronchiectasis often coexists with other respiratory conditions, such as chronic obstructive pulmonary disease.
The prevalence of NCFB is reported to be higher in females. The prevalence of NCFB varies among populations, but studies report an overall prevalence ranging from 486 to 1106 per 100,000 persons with an incidence that appears to be rising, particularly in women and older individuals.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market
The Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Non-Cystic Fibrosis Bronchiectasis (NCFB) market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Non-Cystic Fibrosis Bronchiectasis (NCFB) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Key Facts
-
As per DelveInsight’s estimates, in 2018, the prevalence of Non–cystic fibrosis bronchiectasis was estimated to be 812,266 in the 7MM.
-
The United State accounted for the most prevalent cases of Non–cystic fibrosis bronchiectasis among 7MM with 447,083 cases in 2018.
-
Among EU5 countries, Germany had the highest number of prevalent cases of Non–cystic fibrosis bronchiectasis accounting for 45,651 cases in 2018.
-
According to the study conducted by McShane et al., titled “Non-Cystic Fibrosis Bronchiectasis”, the prevalence of bronchiectasis is increasing in the United States. The prevalence increased every year from 2000 to 2007 by an annual percentage change of 8%. Prevalence was also shown to increase with age and peaked at ages 80–84 years.
Key Benefits of Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Report
-
Non-Cystic Fibrosis Bronchiectasis (NCFB) market report provides an in-depth analysis of Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
-
The report will help in developing business strategies by understanding the Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
-
The market report covers the Non-Cystic Fibrosis Bronchiectasis (NCFB) current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
-
The report provides a detailed assessment of the Non-Cystic Fibrosis Bronchiectasis (NCFB) market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Non-Cystic Fibrosis Bronchiectasis (NCFB) Market
The Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Size in the 7MM was found to be USD 1,218 Million in 2018. The market size shall increase during the forecast period owing to the launch of upcoming therapies in the 7MM. Extensive research and development activities of pharmaceutical companies will also significantly impact market growth.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Non-Cystic Fibrosis Bronchiectasis (NCFB) market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Non-Cystic Fibrosis Bronchiectasis (NCFB) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Request for Sample @ Non-Cystic Fibrosis Bronchiectasis (NCFB) Therapeutics Market Assessment
Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology
The epidemiology section covers insights about the historical and current Non-Cystic Fibrosis Bronchiectasis (NCFB) patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Non-Cystic Fibrosis Bronchiectasis (NCFB) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Cystic Fibrosis Bronchiectasis (NCFB) market or expected to get launched in the market during the study period. The analysis covers Non-Cystic Fibrosis Bronchiectasis (NCFB) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Non-Cystic Fibrosis Bronchiectasis (NCFB) market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Non-Cystic Fibrosis Bronchiectasis (NCFB) emerging therapies.
The dynamics of the Non‐Cystic Fibrosis Bronchiectasis market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, and incremental healthcare spending across the world.
Non-Cystic Fibrosis Bronchiectasis (NCFB) Companies
-
Zambon
-
Novartis
-
Insmed
-
Aradigm Corporation
And others.
Non-Cystic Fibrosis Bronchiectasis (NCFB) Therapies covered in the report include:
-
INS1007
-
Colistimethate sodium
-
Ciprofloxacin dispersion for inhalation
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Non-Cystic Fibrosis Bronchiectasis (NCFB) Competitive Intelligence Analysis
4. Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Overview at a Glance
5. Non-Cystic Fibrosis Bronchiectasis (NCFB) Disease Background and Overview
6. Non-Cystic Fibrosis Bronchiectasis (NCFB) Patient Journey
7. Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology and Patient Population
8. Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Cystic Fibrosis Bronchiectasis (NCFB) Unmet Needs
10. Key Endpoints of Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment
11. Non-Cystic Fibrosis Bronchiectasis (NCFB) Marketed Products
12. Non-Cystic Fibrosis Bronchiectasis (NCFB) Emerging Therapies
13. Non-Cystic Fibrosis Bronchiectasis (NCFB) Seven Major Market Analysis
14. Attribute Analysis
15. Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Outlook (7 major markets)
16. Non-Cystic Fibrosis Bronchiectasis (NCFB) Access and Reimbursement Overview
17. KOL Views on the Non-Cystic Fibrosis Bronchiectasis (NCFB) Market.
18. Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Drivers
19. Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market
Latest Reports By DelveInsight
Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Insights
Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across Non-Cystic Fibrosis Bronchiectasis (NCFB) market.
Patent Foramen Ovale (PFO) Closure Devices Market
DelveInsight’s ‘Patent Foramen Ovale (PFO) Closure Devices Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Patent Foramen Ovale Closure Devices and the historical and forecasted Patent Foramen Ovale Closure Devices market trends in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/